Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Forte Biosciences, Inc.NASDAQ: FBRX
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 133.3% from a year ago
Common stock stood at $14K at the end of Q1 FY2026, up 133.3% from a year earlier and up 7.7% from the prior quarter. Over 3 fiscal years it compounded at -14.8% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +133.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 13K USD
- Year-over-year change
- +116.7%
- 4-year CAGR
- -3.5%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13K | +116.7% |
| FY2024 | 2024-12-31 | 6K | -83.3% |
| FY2023 | 2023-12-31 | 36K | +71.4% |
| FY2022 | 2022-12-31 | 21K | +40.0% |
| FY2021 | 2021-12-31 | 15K | — |
Common Stock vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +133.3% is the highest of 10, against a peer median of +16.3%.
- Common stock amounts to 0.0% of total assets for FBRX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 4.02M CHF | -0.3% | +3.9% | 4.6% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $186K USD | +16.3% | +290.0% | 0.8% |
| Mar 2026 | $116K USD | +0.9% | +5.8% | 0.0% | |
| Mar 2026 | $14K USD | +133.3% | -14.8% | 0.0% | |
| Mar 2026 | $11K USD | +22.2% | +11.2% | 0.0% | |
| Mar 2026 | $7K USD | +133.3% | +51.8% | 0.0% | |
| Mar 2026 | $7K USD | +0.0% | +11.9% | 0.0% | |
| Mar 2026 | $7K USD | +0.0% | +20.5% | 0.0% | |
| Mar 2026 | $2K USD | +100.0% | +68.6% | 0.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $24 USD | +20.0% | +97.2% | 0.0% |
| Peer median (excluding FBRX) | — | +16.3% | +20.5% | 0.0% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.